Skip to content

Diagnostics for cardiotoxicity

Cardiotoxicity from anticancer therapy is a direct effect of cancer treatment on heart function and structure and one of the most common toxicities of cancer treatment, leading to accelerated development of cardiovascular disease. More than one in ten cancer patients do not die from their cancer but from heart and blood vessel problems instead. There is opportunity to support better outcomes by earlier intervention and management of the heart.

Diagnosing and managing cardiotoxicity

Advances in cancer detection and treatment have resulted in a growing number of people surviving the disease. Some chemotherapies, especially anthracyclines and trastuzumab can lead to long-term heart problems, or cancer therapy-related cardiac dysfunction (CTRCD), including left ventricular (LV) systolic dysfunction, pericardial disease, and valvular heart disease.

Echocardiography has a vital role to play in monitoring the cardiotoxicities associated with cancer treatment, however the simple and widely available assessment of left-ventricular ejection fraction (LVEF)  often fails to detect the small changes in LV contractility. More accurate measurements are available using AI and global longitudinal strain (GLS) for the early detection of subclinical LV dysfunction.

Cardio-oncology guidelines recommend echocardiography

Published in March 2021, the British Society of Echocardiography (BSE) and the British Cardio-Oncology Society (BCOS) Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab, aims to unite sonographers and oncologists around this common goal.

The guidelines recommend clinicians obtain volumes, left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS), at baseline, for accurate assessment of LV systolic function.


AI-assisted heart care after cancer treatment

EchoGo is a ground-breaking solution that simplifies echo reporting by using certified, award-winning, cloud-based analysis.

Experience a ground-breaking service that is precise, accurate and efficient, calculating the most widely used measurements useful in managing the heart after cancer care, including those set out in the cardio-oncology guidelines. 

EchoGo Core: Automated LV analysis

We calculate the most common measurements helpful in the diagnoses of heart health, including Global Longitudinal Strain (GLS), Ejection Fraction (EF), Left ventricle end-diastolic volume (LV EDV), Left ventricle end-systolic volume (LV ESV), Left ventricle end-diastolic length (LVL ED), Left ventricle end-systolic length (LVL ES) – from 4C, A2C, A4C/A2C, A3C, A4C/A2C/A3C views and Biplane.


Zero variability between operators.


Save up to 25% of study time.


Clinically validated to outperform manual analysis.

Study highlight call out - cardiotox

"EchoGo provides accurate results such as LV Longitudinal Strain, which we have proven correlate strongly to mortality. This level of accuracy can support physicians at every level be confident to use the results to help diagnose and manage their patients."

Dr Federico M. Asch,

Director of the Echocardiography Core Lab at MedStar Health Research Institute

Discover how you can integrate AI in your workflow to diagnose cardiotoxicity